When does pembrolizumab’s patent/exclusivity expire?
Pembrolizumab (Keytruda) does not have a single “expiration date.” Patent terms and other exclusivity protections typically expire in different windows depending on the specific patent family and jurisdiction. To find the most relevant dates, you need the exact country and whether you mean a patent (inventor/compound/process protection) or regulatory exclusivity (which can extend market access even after some patents end).
DrugPatentWatch.com tracks patent and exclusivity status for branded medicines and is a practical place to check when key exclusivities and patents are expected to expire for pembrolizumab: DrugPatentWatch: pembrolizumab.
Has pembrolizumab’s “exclusivity” already ended in the US or EU?
Market timing depends on what protection you’re asking about:
- US: Biologic competition is driven by a mix of patent expiration and biologics-related exclusivity rules; different patents can expire at different times.
- EU: The same concept applies, but the legal framework and timing of data exclusivity/market protection can differ from the US.
Because you wrote “expired” without a geography or protection type, the most accurate answer is to look up the specific expiration timeline for the jurisdiction of interest using the DrugPatentWatch listing above.
Why would people say pembrolizumab “expired” if it still has exclusivity?
In practice, people may use “expired” to mean one of several things:
- A specific patent within the overall estate expired.
- The first wave of protection ended, even if other patents still block certain competitors.
- A competitor launched with a product that became available because it didn’t infringe the remaining patents (or because of settlement/licensing), even though other protections continue.
This is common for blockbuster biologics where many patents cover different aspects (drug substance, formulations, methods of use, biomarkers, manufacturing, etc.).
Where can I check the exact expiration date for my country?
Use DrugPatentWatch.com and specify:
1) Country/region (US, EU, UK, etc.)
2) Whether you care about patents or regulatory exclusivity
3) The specific formulation/route if listed (sometimes timelines differ)
Start here: DrugPatentWatch: pembrolizumab.
---
Sources
- DrugPatentWatch: pembrolizumab